Hypersecretory Conditions – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Hypersecretory Conditions – Drugs In Development, 2024 report and make more profitable business decisions.
Hypersecretory Condition is a group of disorders characterized by hypersecretion of gastric acid also known as hypergastrinemia. This condition can result in peptic ulcers, GERD, gastrointestinal hemorrhage causing a predominant mortality and morbidity. Underlying diseases, helicobacter pylori infection, gastric outlet obstruction, chronic renal failure and idiopathic causes results to hypersecretion of gastric juice. Diagnosed by the gastrin levels and gastric acid secretion range. Proton pump inhibitors are first line of therapy followed by antibiotics in H. Pylori infections, and supportive care and diet balance by avoiding foods that are citrus in nature. Surgical options in complicated cases.
The Hypersecretory Conditions drugs in development market research report provide comprehensive information on the therapeutics under development for Hypersecretory Conditions, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypersecretory Conditions and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Hypersecretory Conditions | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 11 molecules, with 11 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Hypersecretory Conditions therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Hypersecretory Conditions pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hypersecretory Conditions treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AB Science SAAllakos Inc
Arog Pharmaceuticals Inc
Blueprint Medicines Corp
Cogent Biosciences Inc
CStone Pharmaceuticals Co Ltd
Hoth Therapeutics Inc
Invea Therapeutics Inc
MacroGenics Inc
Seagen Inc
Stemline Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Hypersecretory Conditions reports